The article deals with the issue of health care, focusing on expenditure allocated to it. The first part of the article reviews some selected European Union countries, analyzing their expenditure on their health care sectors. The second part brings an analysis of expenditure on health care in...

Healthcare in Poland is mainly financed by public sector entities, among them the National Health Fund (NFZ), state budget and local government budgets. The task of the National Health Fund, as the main payer in the system, is chiefly currently financing the services. The state budget plays a...

This paper describes the properties and components of integrated hospital IT systems, and the correlations of those comprehensive systems with the use of tools supporting financial management of the units. The first part discusses the essence of Integrated IT Systems and attempts to apply the...

The aging population, the increasing number of lifestyle diseases and the increasing proportion of difficult-to-cure illnesses in the EU demands the use of modern medicine and modern medical technology. Such a situation leads to an increase of funds spent on the health sector. Therefore the...

Healthcare in European countries is provided through different systems run at national levels. The aim of the article is to evaluate selected health care indicators in EU countries, while accentuating similarities and differences between the EU countries in the context of health care systems....

The medical services market in Poland is financed mainly with funds from national health insurance, yet year by year, an increasing importance of private resources in financing health services can be noticed. Apart from common (national) health insurance, medical care is primarily financed...

Healthcare is a very important, and at the same time difficult element of each state’s policy. For many countries, the issue of financing the healthcare system is a delicate matter, while at the same time one of the basic economic and social issues. Nevertheless, decisions concerning the...

The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety. In May 2019, the European Medicines Agency (EMA) search engine showed 54 authorized biosimilars. Biosimilars...